

1/1
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44268 A1

(51) International Patent Classification²: C07J 41/00, Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).
A61K 31/565, A61P 5/32

(21) International Application Number: PCT/GB00/04689 (74) Agents: ALCOCK, David et al.; D Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).

(22) International Filing Date: 7 December 2000 (07.12.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
9929445.6 13 December 1999 (13.12.1999) GB
0004317.4 23 February 2000 (23.02.2000) GB
0018040.6 21 July 2000 (21.07.2000) GB



(71) Applicant (for all designated States except US): STERIX LIMITED [GB/GB]; Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HALOGENATED SULPHAMATE-, PHOSPHONATE-, THIOPHOSPHONATE-, SULPHONATE- AND SULPHONAMIDE- COMPOUNDS AS INHIBITORS OF STEROID SULPHATASE



(57) Abstract: A compound is described. The compound has the formula (Ia) as presented in the Figure 1; wherein: X is a ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group. The compound is capable of inhibiting steroid sulphatase (STS) activity.

HALOGENATED SULPHAMATE-, PHOSPHONATE-, THIOPHOSPHONATE-, SULPHONATE- AND SULPHONAMIDE- COMPOUNDS AS INHIBITORS OF STEROID SULPHATASE

FIELD OF INVENTION

5 The present invention relates to a compound.

In particular the present invention relates to a compound and to a pharmaceutical composition comprising the compound. The present invention also relates to the use of the compound or composition in therapy applications.

10

BACKGROUND TO THE INVENTION

Evidence suggests that oestrogens are the major mitogens involved in promoting the growth of tumours in endocrine-dependent tissues, such as the breast and endometrium.

15 Although plasma oestrogen concentrations are similar in women with or without breast cancer, breast tumour oestrone and oestradiol levels are significantly higher than in normal breast tissue or blood. *In situ* synthesis of oestrogen is thought to make an important contribution to the high levels of oestrogens in tumours and therefore inhibitors, in particular specific inhibitors, of oestrogen biosynthesis are of potential value for the

20 treatment of endocrine-dependent tumours.

Over the past two decades, there has been considerable interest in the development of inhibitors of the aromatase pathway - which converts the androgen precursor androstenedione to oestrone. However, there is now evidence that the oestrone sulphatase (E1-STS) pathway, i.e. the hydrolysis of oestrone sulphate to oestrone (E1S to E1), as opposed to the aromatase pathway, is the major source of oestrogen in breast tumours. This theory is supported by a modest reduction of plasma oestrogen concentration in postmenopausal women with breast cancer treated by aromatase inhibitors, such as aminoglutethimide and 4-hydroxyandrostenedione, and also by the fact


25 that plasma E1S concentration in these aromatase inhibitor-treated patients remains relatively high. The long half-life of E1S in blood (10-12 h) compared with the unconjugated oestrogens (20 min) and high levels of steroid sulphatase activity in liver and, normal and malignant breast tissues, also lend support to this theory.

30

35 PCT/GB92/01587 teaches novel steroid sulphatase inhibitors and pharmaceutical compositions containing them for use in the treatment of oestrone dependent tumours, especially breast cancer. These steroid sulphatase inhibitors are sulphamate esters,

such as N,N-dimethyl oestrone-3-sulphamate and, preferably, oestrone-3-sulphamate (otherwise known as "EMATE").

5 EMATE (2-methoxyoestrone-3-O-sulphamate) – which is an analogue of oestrone-3-O-sulphamate - has the following structure:



10 It is known that EMATE is a potent E1-STS inhibitor as it displays more than 99% inhibition of E1-STS activity in intact MCF-7 cells at 0.1 mM. EMATE also inhibits the E1-STS enzyme in a time- and concentration-dependent manner, indicating that it acts as an active site-directed inactivator. Although EMATE was originally designed for the inhibition of E1-STS, it also inhibits dehydroepiandrosterone sulphatase (DHA-STS), which is an enzyme that is believed to have a pivotal role in regulating the biosynthesis of the oestrogenic steroid androstenediol. Also, there is now evidence to suggest that androstenediol may be of even greater importance as a promoter of breast tumour growth. EMATE is also active in vivo as almost complete inhibition of rat liver E1-STS (99%) and DHA-STS (99%) activities resulted when it is administered either orally or subcutaneously. In addition, EMATE has been shown to have a memory enhancing effect in rats. Studies in mice have suggested an association between DHA-STS activity and the regulation of part of the immune response. It is thought that this may also occur in humans. The bridging O-atom of the sulphamate moiety in EMATE is important for inhibitory activity. Thus, when the 3-O-atom is replaced by other heteroatoms as in oestrone-3-N-sulphamate and oestrone-3-S-sulphamate, these analogues are weaker 15 non-time-dependent inactivators.

20

25

Although optimal potency for inhibition of E1-STS may have been attained in EMATE, it is possible that oestrone may be released during sulphatase inhibition and that EMATE and its oestradiol congener may possess oestrogenic activity.

Ahmed et al (Biochem Biophys Res Commun 1999 Jan 27;254(3):811-5) report on a structure-activity relationship study of steroidal and nonsteroidal inhibitors of STS.

The present invention seeks to provide novel compounds suitable for the inhibition of E1-
5 STS as well as other therapeutic applications.

SUMMARY ASPECTS OF THE PRESENT INVENTION

The present invention is based on the surprising finding that certain halo-compounds
10 could be used as effective steroid sulphatase inhibitors.

The halo compounds comprise at least one halo group that is a substituent of a ring system compound. The ring system compounds comprise at least one ring component. That ring component comprises at least 4 atoms in the ring. Typically, those 4 atoms will
15 be carbon atoms. Thus, typically, that ring component will be a hydrocarbyl group. The ring system compound also includes one or more of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group as further substituent(s) on the ring system. At least one of the sulphamate group, the phosphonate group, the thiophosphonate group, the sulphonate group or the sulphonamide group is a
20 substituent on the ring component. In a preferred aspect, the halo group(s) will be substituents on atom(s) that are adjacent the atom which bears the at least one sulphamate group, phosphonate group, thiophosphonate group, sulphonate group or sulphonamide group.

25 The halo compounds of the present invention may comprise other substituents. These other substituents may, for example, further increase the activity of the compounds of the present invention and/or increase stability (ex vivo and/or in vivo).

DETAILED ASPECTS OF THE PRESENT INVENTION

30 According to one aspect of the present invention, there is provided a compound of the formula (Ia) as presented in Figure 1; wherein: X is a hydrocarbyl ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a
35 sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity.

According to one aspect of the present invention, there is provided a method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula (Ia); (b) determining whether one or more of said candidate compounds is/are 5 capable of modulating STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of modulating STS activity.

According to one aspect of the present invention, there is provided a method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having 10 the formula (Ia); (b) determining whether one or more of said candidate compounds is/are capable of inhibiting STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting STS activity.

In any one of the methods of the present invention, one or more additional steps may be 15 present. For example, the method may also include the step of modifying the identified candidate compound (such as by chemical and/or enzymatic techniques) and the optional additional step of testing that modified compound for STS inhibition effects (which may be to see if the effect is greater or different). By way of further example, the method may 20 also include the step of determining the structure (such as by use of crystallographic techniques) of the identified candidate compound and then performing computer modelling studies – such as to further increase its STS inhibitory action. Thus, the present invention also encompasses a computer having a dataset (such as the crystallographic co-ordinates) for said identified candidate compound. The present invention also encompasses that identified candidate compound when presented on a 25 computer screen for the analysis thereof – such as protein binding studies.

According to one aspect of the present invention, there is provided a compound identified by the method of the present invention. 30 According to one aspect of the present invention, there is provided a compound according to the present invention for use in medicine.

According to one aspect of the present invention, there is provided a pharmaceutical composition comprising the compound according to the present invention optionally 35 admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

According to one aspect of the present invention, there is provided the use of a compound according to the present invention in the manufacture of a medicament for use in the therapy of a condition or disease associated with STS.

5 According to one aspect of the present invention, there is provided the use of a compound according to the present invention in the manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels.

For ease of reference, these and further aspects of the present invention are now 10 discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.

PREFERABLE ASPECTS

15 Preferably, X in combination with Y mimics a steroid structure.

Preferably, K is a cyclic group.

Preferably, X is a six-membered ring.

20 Preferably, the ring X has six carbon atoms in the ring.

Preferably, X in combination with Y is a steroid ring structure.

25 Preferably, group K and ring X are a steroid ring structure or a substituted derivative thereof.

Preferably, the Rs group is at position 3 of the ring X.

30 Preferably, Rs is a sulphamate group.

Preferably, the Rh1 is at position 2 of the ring X.

Preferably, the Rh2 is at position 4 of the ring X.

Preferably, the compound of formula (Ia) has the formula presented as formula (Ib) wherein each of Rh1, Rh2, Rs, X and K have the above-mentioned meanings, and wherein at least one of Rh1 and Rh2 is present.

5 Preferably the group K and the ring X together will contain, inclusive of all substituents, a maximum of about 50 carbon atoms, more usually no more than about 30 to 40 carbon atoms.

10 For some applications, preferably the compounds have no, or a minimal, oestrogenic effect.

For some applications, preferably the compounds have an oestrogenic effect.

For some applications, preferably the compounds have a reversible action.

15 For some applications, preferably the compounds have an irreversible action.

In one embodiment, the compounds of the present invention are useful for the treatment of breast cancer.

20 Two preferred compounds are: 2-IodoEMATE and 2-BromoEMATE.

SOME ADVANTAGES

25 One key advantage of the present invention is that the sulphamate compounds of the present invention can act as STS inhibitors.

Another advantage of the compounds of the present invention is that they may be potent *in vivo*.

30 Some of the compounds of the present invention may be non-oestrogenic compounds. Here, the term "non-oestrogenic" means exhibiting no or substantially no oestrogenic activity.

35 Another advantage is that some of the compounds may not be capable of being metabolised to compounds which display or induce hormonal activity.

Some of the compounds of the present invention are also advantageous in that they may be orally active.

Some of the compounds of the present invention may be useful for the treatment of cancer, 5 such as breast cancer, as well as (or in the alternative) non-malignant conditions, such as the prevention of auto-immune diseases, particularly when pharmaceuticals may need to be administered from an early age.

Thus, some of the compounds of the present invention are also believed to have 10 therapeutic uses other than for the treatment of endocrine-dependent cancers, such as the treatment of autoimmune diseases.

STEROID SULPHATASE

15 Steroid sulphatase – which is sometimes referred to as steroid sulfatase or steryl sulphatase or "STS" for short – hydrolyses several sulphated steroids, such as oestrone sulphate, dehydroepiandrosterone sulphate and cholesterol sulphate. STS has been allocated the enzyme number EC 3.1.6.2.

20 STS has been cloned and expressed. For example see Stein *et al* (J. Biol. Chem. 264:13865-13872 (1989)) and Yen *et al* (Cell 49:443-454(1987)).

STS is an enzyme that has been implicated in a number of disease conditions.

25 By way of example, workers have found that a total deficiency in STS produces ichthyosis. According to some workers, STS deficiency is fairly prevalent in Japan. The same workers (Sakura *et al*, J Inherit Metab Dis 1997 Nov;20(6):807-10) have also reported that allergic diseases – such as bronchial asthma, allergic rhinitis, or atopic dermatitis - may be associated with a steroid sulphatase deficiency.

30 In addition to disease states being brought on through a total lack of STS activity, an increased level of STS activity may also bring about disease conditions. By way of example, and as indicated above, there is strong evidence to support a role of STS in breast cancer growth and metastasis.

35 STS has also been implicated in other disease conditions. By way of example, Le Roy *et al* (Behav Genet 1999 Mar;29(2):131-6) have determined that there may be a genetic

correlation between steroid sulphatase concentration and initiation of attack behaviour in mice. The authors conclude that sulphatation of steroids may be the prime mover of a complex network, including genes shown to be implicated in aggression by mutagenesis.

5 STS INHIBITION

It is believed that some disease conditions associated with STS activity are due to conversion of a nonactive, sulphated oestrone to an active, nonsulphated oestrone. In disease conditions associated with STS activity, it would be desirable to inhibit STS 10 activity.

Here, the term "inhibit" includes reduce and/or eliminate and/or mask and/or prevent the detrimental action of STS.

15 STS INHIBITOR

In accordance with the present invention, the compound of the present invention is capable of acting as an STS inhibitor.

20 Here, the term "inhibitor" as used herein with respect to the compound of the present invention means a compound that can inhibit STS activity – such as reduce and/or eliminate and/or mask and/or prevent the detrimental action of STS. The STS inhibitor may act as an antagonist.

25 The ability of compounds to inhibit oestrone sulphatase activity can be assessed using either intact MCF-7 breast cancer cells or placental microsomes. In addition, an animal model may be used. Details on suitable Assay Protocols are presented in following sections. It is to be noted that other assays could be used to determine STS activity and thus STS inhibition. For example, reference may also be made to the teachings of WO- 30 A-99/50453.

35 Preferably, for some applications, the compound is further characterised by the feature that if the sulphamate group were to be substituted by a sulphate group to form a sulphate derivative, then the sulphate derivative would be hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity - i.e. when incubated with steroid sulphatase EC 3.1.6.2 at pH 7.4 and 37°C.

In one preferred embodiment, if the sulphamate group of the compound were to be replaced with a sulphate group to form a sulphate compound then that sulphate compound would be hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity and would yield a K_m value of less than 200 mmolar, preferably less than 150 mmolar, preferably less than 100 mmolar, preferably less than 75 mmolar, preferably less than 50 mmolar, when incubated with steroid sulphatase EC 3.1.6.2 at pH 7.4 and 37°C.

In a preferred embodiment, the compound of the present invention is not hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity.

For some applications, preferably the compound of the present invention has at least about a 100 fold selectivity to a desired target (e.g. STS), preferably at least about a 150 fold selectivity to the desired target, preferably at least about a 200 fold selectivity to the desired target, preferably at least about a 250 fold selectivity to the desired target, preferably at least about a 300 fold selectivity to the desired target, preferably at least about a 350 fold selectivity to the desired target.

It is to be noted that the compound of the present invention may have other beneficial properties in addition to or in the alternative to its ability to inhibit STS activity.

20 **GROUP K**

Group K need not be a cyclic structure. In this regard, group K may be a linear structure that may have the ability to conform to a ring like structure when in *in vivo*.

25 In a preferred aspect, group K is cyclic - so as to form the cyclic group K.

Cyclic group K need not necessarily be fused to ring X. In this regard, they may be separated by a suitable spacer group – which may be a hydrocarbyl group.

30 In a preferred aspect, cyclic group K is fused to ring X.

Group K may be a polycyclic group, which need not be a fused polycycle.

35 Thus, in a preferred aspect, group K and ring X make up a polycyclic compound. As indicated, here the term "polycyclic" includes fused and non-fused ring structures including combinations thereof.

At least one of the cyclic groups K and X may be a heterocyclic group (a heterocycle) or a non-heterocyclic group.

5 At least one of the cyclic groups K and X may be a saturated ring structure or an unsaturated ring structure (such as an aryl group).

Preferably, at least one of the cyclic groups is an aryl ring.

10 If the cyclic group is polycyclic some or all of the ring components of the compound may be fused together or joined via one or more suitable spacer groups.

) The polycyclic compound may comprise a number of fused rings. In this aspect the fused rings may comprise any combination of different size rings, such as 3 six-membered rings
15 15 a six-membered ring, a seven-membered ring and a six-membered ring (6,7,6), a six-membered ring and two eight-membered rings (6,8,8) etc.

In one aspect the present invention relates to compounds wherein the polycyclic compounds are other than (6,6,7) rings. In a further aspect, the present invention relates to
20 compounds wherein the polycyclic compounds only contain rings having other than 7 members.

Preferably the polycyclic compound will contain, inclusive of all substituents, no more than 50 about carbon atoms, more usually no more than about 30 to 40 carbon atoms.

25 The polycyclic compound can comprise at least two ring components, or at least three ring components, or at least four ring components.

Preferably, the polycyclic compound comprises four ring components.

30 Preferred polycyclic compounds have a steroidal ring component, or bio-isosteres thereof.

HYDROCARBYL

35 The term "hydrocarbyl group" as used herein means a group comprising at least C and H and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, an alkyl group, a cyclic group etc. In addition

to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may 5 contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur, nitrogen and oxygen. A non-limiting example of a hydrocarbyl group is an acyl group.

A typical hydrocarbyl group is a hydrocarbon group. Here the term "hydrocarbon" means 10 any one of an alkyl group, an alkenyl group, an alkynyl group, which groups may be linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the 15 hydrocarbon backbone and on the branch.

SULPHAMATE GROUP

In one embodiment, the ring X has a sulphamate group as a substituent. The term 20 "sulphamate" as used herein includes an ester of sulphamic acid, or an ester of an N-substituted derivative of sulphamic acid, or a salt thereof.

If Rs is a sulphamate group then the compound of the present invention is referred to as 25 a sulphamate compound.

Typically, the sulphamate group has the formula:



30 wherein preferably R1 and R2 are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

35 When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R1 and/or R2 is alkyl, the preferred

values are those where R1 and R2 are each independently selected from lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. R1 and R2 may both be methyl. When R1 and/or R2 is aryl, typical values are phenyl and tolyl (PhCH₃; o). Where R1 and R2 represent cycloalkyl, typical values are cyclopropyl, 5 cyclopentyl, cyclohexyl etc. When joined together R1 and R2 typically represent an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.

10 Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.

15 In some embodiments, the sulphamate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.

In some embodiments, there may be more than one sulphamate group. By way of example, there may be two sulphamates (i.e. bis-sulphamate compounds). If these 20 compounds are based on a steroid nucleus, preferably the second (or at least one of the additional) sulphamate group is located at position 17 of the steroid nucleus. These groups need not be the same.

In some preferred embodiments, at least one of R1 and R2 is H.

25

In some further preferred embodiments, each of R1 and R2 is H.

PHOSPHONATE GROUP

30 If R_s is a phosphonate group then the compound of the present invention is referred to as a phosphonate compound.

Typically, the phosphonate group has the formula:

35

(R1)-P(O)(OH)-O-

wherein preferably R1 is H, alkyl, cycloalkyl, alkenyl or aryl, or combinations thereof, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

- 5 When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R1 is alkyl, R1 may be a lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. By way of example, R1 may be methyl. When R1 is aryl, typical values are phenyl and tolyl
- 10 Where R1 represents cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. R1 may even comprise an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.
- 15 Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.
- 20 In some embodiments, the phosphonate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.


In some embodiments, there may be more than one phosphonate group. By way of example, there may be two phosphonates (i.e. bis-phosphonate compounds). If these 25 compounds are based on a steroidal nucleus, preferably the second (or at least one of the additional) phosphonate group is located at position 17 of the steroidal nucleus. These groups need not be the same.

THIOPHOSPHONATE GROUP

- 30 If Rs is a thiophosphonate group then the compound of the present invention is referred to as a thiophosphonate compound.

Typically, the thiophosphonate group has the formula:

35



wherein preferably R1 is H, alkyl, cycloalkyl, alkenyl or aryl, or combinations thereof, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

- 5 When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R1 is alkyl, R1 may be a lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. By way of example, R1 may be methyl. When R1 is aryl, typical values are phenyl and tolyl (PhCH₃; o). Where R1 represents cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. R1 may even comprise an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.
- 10
- 15 Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.
- 20 In some embodiments, the thiophosphonate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.
- 25 In some embodiments, there may be more than one thiophosphonate group. By way of example, there may be two thiophosphonates (i.e. bis-thiophosphonate compounds). If these compounds are based on a steroid nucleus, preferably the second (or at least one of the additional) thiophosphonate group is located at position 17 of the steroid nucleus. These groups need not be the same.


SULPHONATE GROUP

30

If R_s is a sulphonate group then the compound of the present invention is referred to as a sulphonate compound.

Typically, the sulphonate group has the formula:

35



wherein preferably R1 is H, alkyl, cycloalkyl, alkenyl or aryl, or combinations thereof, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

- 5 When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R1 is alkyl, R1 may be a lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. By way of example, R1 may be methyl. When R1 is aryl, typical values are phenyl and tolyl (PhCH₃; o). Where R1 represents cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. R1 may even comprise an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.
- 10
- 15 Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.
- 20 In some embodiments, the sulphonate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.

In some embodiments, there may be more than one sulphonate group. By way of example, there may be two sulphonates (i.e. bis- sulphonate compounds). If these compounds are based on a steroid nucleus, preferably the second (or at least one of the additional) sulphonate group is located at position 17 of the steroid nucleus. These groups need not be the same.

COMBINATION SULPHONATE/PHOSPHONATE/THIOPHOSPHONATE/SULPHAMATE

30

- For some compounds of the present invention there may be present one of a sulphonate as herein defined or a phosphonate as herein defined or a thiophosphonate as herein defined or a sulphamate as herein defined; and another of a sulphonate as herein defined or a phosphonate as herein defined or a thiophosphonate as herein defined or a sulphamate as herein defined. By way of example, the compound of the present invention may comprise one sulphamate group and one phosphonate group.
- 35

If these compounds of the present invention are based on a steroid nucleus, preferably the other of said groups is located at position 17 of the steroid nucleus.

MIMIC

5

In one aspect, X and K can be a mimic of a steroid ring structure

The term "mimic" as used herein means having a similar or different structure but having a similar functional effect. In other words, group K and ring X together may be a bio-



10 isostere of the rings of a steroid, or an active part thereof.

In a preferred aspect, group K and ring X together may be a bio-isostere of the rings of oestrone, or a part thereof.

15 STEROIDAL RING STRUCTURE

In one preferred aspect, X and K make up a steroid ring structure - that is to say a cyclopentanophenanthrene skeleton, or bio-isosteres thereof.


20 As it is well known in the art, a classical steroid ring structure has the generic formula of:



In the above formula, the rings have been labelled in the conventional manner.

An example of a bio-isostere is when any one or more of rings A, B, C and D is a heterocyclic ring and/or when any one or more of rings A, B, C and D has been substituted and/or when any one or more of rings A, B, C and D has been modified; but wherein the bio-isostere in the absence of the sulphamate group has steroidal properties.

In this regard, the structure of a preferred polycyclic structure can be presented as:



10

wherein each ring A', B', C' and D' independently represents a heterocyclic ring or a non-heterocyclic ring, which rings may be independently substituted or unsubstituted, saturated or unsaturated.

15

By way of example, any one or more of rings A', B', C' and D' may be independently substituted with suitable groups - such as an alkyl group, an aryl group, a hydroxy group, a halo group, a hydrocarbyl group, an oxyhydrocarbyl group etc.

20 An example of D' is a five or six membered non-heterocyclic ring having at least one substituent.

In one preferred embodiment, the ring D' is substituted with an ethynyl group.

25 If any one of rings A', B', C' and D' is a heterocyclic ring, then preferably that heterocyclic ring comprises a combination of C atoms and at least one N atom and/or at least one O atom. Other heterocyclic atoms may be present in the ring.

Examples of suitable, preferred steroid nuclei rings A'-D' of the compounds of the present
30 invention include rings A-D of dehydroepiandrosterone and oestrogens including oestrone.

Preferred steroid nuclei rings A'-D' of the compounds of the present invention include rings A-D of:

oestrones and substituted oestrones, viz:

- oestrone
- 4-OH-oestrone
- 5 6 α -OH-oestrone
- 7 α -OH-oestrone
- 16 α -OH-oestrone
- 16 β -OH-oestrone
- 17-deoxyoestrone
- 10 oestrone

oestradiols and substituted oestradiols, viz:

- 4-OH-17 β -oestradiol
- 6 α -OH-17 β -oestradiol
- 15 7 α -OH-17 β -oestradiol
- 4-OH-17 α -oestradiol
- 6 α -OH-17 α -oestradiol
- 7 α -OH-17 α -oestradiol
- 16 α -OH-17 α -oestradiol
- 20 16 α -OH-17 β -oestradiol
- 16 β -OH-17 α -oestradiol
- 16 β -OH-17 β -oestradiol
- 17 α -oestradiol
- 17 β -oestradiol
- 25 17 α -ethinyl-17 β -oestradiol
- 17 β -ethinyl-17 α -oestradiol
- 17-deoxyoestradiol

oestriols and substituted oestriols, viz:

- 30 oestriol
- 4-OH-oestriol
- 6 α -OH-oestriol
- 7 α -OH-oestriol
- 17-deoxyoestriol

dehydroepiandrosterones and substituted dehydroepiandrosterones, viz:

dehydroepiandrosterones
6 α -OH-dehydroepiandrosterone
7 α -OH-dehydroepiandrosterone
5 16 α -OH-dehydroepiandrosterone
16 β -OH-dehydroepiandrosterone

In general terms the ring system A'B'C'D' may contain a variety of non-interfering substituents. In particular, the ring system A'B'C'D' may contain one or more hydroxy, alkyl especially lower (C₁-C₆) alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and other pentyl isomers, and n-hexyl and other hexyl isomers, alkoxy especially lower (C₁-C₆) alkoxy, e.g. methoxy, ethoxy, propoxy etc., alkinyl, e.g. ethinyl, or halogen, e.g. fluoro substituents.

15 NON-STEROID STRUCTURES

In an alternative embodiment, the compound of the present invention may not contain or be based on a steroid nucleus. In this regard, the polycyclic compound may contain or be based on a non-steroidal ring system - such as diethylstilboestrol, stilboestrol, coumarins, 20 flavonoids, combrestatin and other ring systems. Other suitable non-steroidal compounds for use in or as the composition of the present invention may be found in US-A-5567831.

OTHER SUBSTITUENTS

25 The compound of the present invention may have substituents other than Rh1, Rh2 and Rs. By way of example, these other substituents may be one or more of: one or more sulphamate group(s), one or more phosphonate group(s), one or more thiophosphonate group(s), one or more sulphonate group(s), one or more sulphonamide group(s), one or more halo groups, one or more O groups, one or more hydroxy groups, one or more 30 amino groups, one or more sulphur containing group(s), one or more hydrocarbyl group(s) – such as an oxyhydrocarbyl group.

OXYHYDROCARBYL

35 The term "oxyhydrocarbyl" group as used herein means a group comprising at least C, H and O and may optionally comprise one or more other suitable substituents. Examples of

such substituents may include halo-, alkoxy-, nitro-, an alkyl group, a cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the oxyhydrocarbyl group comprises more than one C then those carbons need not necessarily be linked to each other. For example, at 5 least two of the carbons may be linked via a suitable element or group. Thus, the oxyhydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur and nitrogen.

In one embodiment of the present invention, the oxyhydrocarbyl group is a 10 oxyhydrocarbon group.

Here the term "oxyhydrocarbon" means any one of an alkoxy group, an oxyalkenyl group, an oxyalkynyl group, which groups may be linear, branched or cyclic, or an oxyaryl group. The term oxyhydrocarbon also includes those groups but wherein they have been 15 optionally substituted. If the oxyhydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

20 Typically, the oxyhydrocarbyl group is of the formula $C_{1-6}O$ (such as a $C_{1-3}O$).

ASSAY FOR DETERMINING STS ACTIVITY USING CANCER CELLS (PROTOCOL 1)

Inhibition of Steroid Sulphatase Activity in MCF-7 cells

25 Steroid sulphatase activity is measured *in vitro* using intact MCF-7 human breast cancer cells. This hormone dependent cell line is widely used to study the control of human breast cancer cell growth. It possesses significant steroid sulphatase activity (MacIndoe et al. Endocrinology, 123, 1281-1287 (1988); Purohit & Reed, Int. J. Cancer, 50, 901-905 30 (1992)) and is available in the U.S.A. from the American Type Culture Collection (ATCC) and in the U.K. (e.g. from The Imperial Cancer Research Fund).

Cells are maintained in Minimal Essential Medium (MEM) (Flow Laboratories, Irvine, Scotland) containing 20 mM HEPES, 5% foetal bovine serum, 2 mM glutamine, non- 35 essential amino acids and 0.075% sodium bicarbonate. Up to 30 replicate 25 cm² tissue culture flasks are seeded with approximately 1×10^5 cells/flask using the above medium. Cells are grown to 80% confluence and the medium is changed every third day.

Intact monolayers of MCF-7 cells in triplicate 25 cm² tissue culture flasks are washed with Earle's Balanced Salt Solution (EBSS from ICN Flow, High Wycombe, U.K.) and incubated for 3-4 hours at 37°C with 5 pmol (7 x 10⁵ dpm) [6,7-³H]oestrone-3-sulphate (specific activity 60 Ci/mmol from New England Nuclear, Boston, Mass., U.S.A.) in serum-free MEM (2.5 ml) together with oestrone-3-sulphamate (11 concentrations: 0; 1fM; 0.01pM; 0.1pM; 1pM; 0.01nM; 0.1nM; 1nM; 0.01mM; 0.1mM; 1mM). After incubation each flask is cooled and the medium (1 ml) is pipetted into separate tubes containing [14C]oestrone (7 x 10³ dpm) (specific activity 97 Ci/mmol from Amersham International Radiochemical Centre, Amersham, U.K.). The mixture is shaken thoroughly for 30 seconds with toluene (5 ml). Experiments have shown that >90% [14C] oestrone and <0.1% [3H]oestrone-3-sulphate is removed from the aqueous phase by this treatment. A portion (2 ml) of the organic phase is removed, evaporated and the 3H and 14C content of the residue determined by scintillation spectrometry. The mass of oestrone-3-sulphate hydrolysed was calculated from the 3H counts obtained (corrected for the volumes of the medium and organic phase used, and for recovery of [14C] oestrone added) and the specific activity of the substrate. Each batch of experiments includes incubations of microsomes prepared from a sulphatase-positive human placenta (positive control) and flasks without cells (to assess apparent non-enzymatic hydrolysis of the substrate). The number of cell nuclei per flask is determined using a Coulter Counter after treating the cell monolayers with Zaponin. One flask in each batch is used to assess cell membrane status and viability using the Trypan Blue exclusion method (Phillips, H.J. (1973) In: Tissue culture and applications, [eds: Kruse, D.F. & Patterson, M.K.]; pp. 406-408; Academic Press, New York).

Results for steroid sulphatase activity are expressed as the mean ± 1 S.D. of the total product (oestrone + oestradiol) formed during the incubation period (20 hours) calculated for 106 cells and, for values showing statistical significance, as a percentage reduction (inhibition) over incubations containing no oestrone-3-sulphamate. Unpaired Student's t-test was used to test the statistical significance of results.

ASSAY FOR DETERMINING STS ACTIVITY USING PLACENTAL MICROSONES
(PROTOCOL 2)

35 Inhibition of Steroid Sulphatase Activity in Placental Microsomes

Sulphatase-positive human placenta from normal term pregnancies are thoroughly minced with scissors and washed once with cold phosphate buffer (pH 7.4, 50 mM) then re-suspended in cold phosphate buffer (5 ml/g tissue). Homogenisation is accomplished with an Ultra-Turrax homogeniser, using three 10 second bursts separated by 2 minute 5 cooling periods in ice. Nuclei and cell debris are removed by centrifuging (4°C) at 2000g for 30 minutes and portions (2 ml) of the supernatant are stored at 20°C. The protein concentration of the supernatants is determined by the method of Bradford (Anal. Biochem., 72, 248-254 (1976)).

10 Incubations (1 ml) are carried out using a protein concentration of 100 mg/ml, substrate concentration of 20 mM [6,7-3H]oestrone-3-sulphate (specific activity 60 Ci/mmol from New England Nuclear, Boston, Mass., U.S.A.) and an incubation time of 20 minutes at 37°C. If necessary eight concentrations of compounds are employed: 0 (i.e. control); 0.05mM; 0.1mM; 0.2mM; 0.4mM; 0.6mM; 0.8mM; 1.0mM. After incubation each sample 15 is cooled and the medium (1 ml) was pipetted into separate tubes containing [14C]oestrone (7 x 103 dpm) (specific activity 97 Ci/mmol from Amersham International Radiochemical Centre, Amersham, U.K.). The mixture is shaken thoroughly for 30 seconds with toluene (5 ml). Experiments have shown that >90% [14C]oestrone and <0.1% [3H]oestrone-3-sulphate is removed from the aqueous phase by this treatment. A 20 portion (2 ml) of the organic phase was removed, evaporated and the 3H and 14C content of the residue determined by scintillation spectrometry. The mass of oestrone-3-sulphate hydrolysed is calculated from the 3H counts obtained (corrected for the volumes of the medium and organic phase used, and for recovery of [14C]oestrone added) and the specific activity of the substrate.

25

ANIMAL ASSAY MODEL FOR DETERMINING STS ACTIVITY (PROTOCOL 3)

Inhibition of oestrone sulphatase activity *in vivo*

30 The compounds of the present invention may be studied using an animal model, in particular in ovariectomised rats. In this model compounds which are oestrogenic stimulate uterine growth.

35 The compound (0.1 mg/Kg/day for five days) is administered orally to rats with another group of animals receiving vehicle only (propylene glycol). At the end of the study samples of liver tissue were obtained and oestrone sulphatase activity assayed using 3H oestrone sulphate as the substrate as previously described (see PCT/GB95/02638).

ANIMAL ASSAY MODEL FOR DETERMINING OESTROGENIC ACTIVITY (PROTOCOL 4)

5 Lack of *in vivo* oestrogenicity

The compounds of the present invention may be studied using an animal model, in particular in ovariectomised rats. In this model, compounds which are oestrogenic stimulate uterine growth.

10 The compound (0.1 mg/Kg/day for five days) was administered orally to rats with another group of animals receiving vehicle only (propylene glycol). At the end of the study uteri were obtained and weighed with the results being expressed as uterine weight/whole body weight x 100.

15 Compounds having no significant effect on uterine growth are not oestrogenic.

BIOTECHNOLOGICAL ASSAYS FOR DETERMINING STS ACTIVITY (PROTOCOL 5)

20 The ability of compounds to inhibit oestrone sulphatase activity can also be assessed using amino acid sequences or nucleotide sequences encoding STS, or active fragments, derivatives, homologues or variants thereof in, for example, high-through put screens.

25 Any one or more of appropriate targets - such as an amino acid sequence and/or nucleotide sequence - may be used for identifying an agent capable of modulating STS in any of a variety of drug screening techniques. The target employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of target activity or the formation of binding complexes between the target and the agent being tested may be measured.

30 The assay of the present invention may be a screen, whereby a number of agents are tested. In one aspect, the assay method of the present invention is a high through put screen.

35 Techniques for drug screening may be based on the method described in Geysen, European Patent Application 84/03564, published on September 13, 1984. In summary, large numbers of different small peptide test compounds are synthesised on a solid

substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with a suitable target or fragment thereof and washed. Bound entities are then detected - such as by appropriately adapting methods well known in the art. A purified target can also be coated directly onto plates for use in a drug screening techniques.

5 Alternatively, non-neutralising antibodies can be used to capture the peptide and immobilise it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralising antibodies capable of binding a target specifically compete with a test 10 compound for binding to a target.

Another technique for screening provides for high throughput screening (HTS) of agents having suitable binding affinity to the substances and is based upon the method described in detail in WO 84/03564.

15 It is expected that the assay methods of the present invention will be suitable for both small and large-scale screening of test compounds as well as in quantitative assays.

In one preferred aspect, the present invention relates to a method of identifying agents 20 that selectively modulate STS, which compounds have the formula (Ia).

REPORTERS

A wide variety of reporters may be used in the assay methods (as well as screens) of the 25 present invention with preferred reporters providing conveniently detectable signals (e.g. by spectroscopy). By way of example, a reporter gene may encode an enzyme which catalyses a reaction which alters light absorption properties.

Other protocols include enzyme-linked immunosorbent assay (ELISA), 30 radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilising monoclonal antibodies reactive to two non-interfering epitopes may even be used. These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, A Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 158:1211).

35 Examples of reporter molecules include but are not limited to β -galactosidase, invertase, green fluorescent protein, luciferase, chloramphenicol, acetyltransferase, β -glucuronidase,

exo-glucanase and glucoamylase. Alternatively, radiolabelled or fluorescent tag-labelled nucleotides can be incorporated into nascent transcripts which are then identified when bound to oligonucleotide probes.

5 By way of further examples, a number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for assay procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and
10 the like. Patents teaching the use of such labels include US-A-3817837; US-A-3850752; US-A-3939350; US-A-3996345; US-A-4277437; US-A-4275149 and US-A-4366241.

HOST CELLS

15 The term "host cell" - in relation to the present invention includes any cell that could comprise the target for the agent of the present invention.

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a polynucleotide that is or expresses the target of the present invention.
20 Preferably said polynucleotide is carried in a vector for the replication and expression of polynucleotides that are to be the target or are to express the target. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.

25 The gram negative bacterium *E. coli* is widely used as a host for heterologous gene expression. However, large amounts of heterologous protein tend to accumulate inside the cell. Subsequent purification of the desired protein from the bulk of *E.coli* intracellular proteins can sometimes be difficult.

30 In contrast to *E.coli*, bacteria from the genus *Bacillus* are very suitable as heterologous hosts because of their capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera *Streptomyces* and *Pseudomonas*.

35 Depending on the nature of the polynucleotide encoding the polypeptide of the present invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some

proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected.

5 Examples of suitable expression hosts within the scope of the present invention are fungi such as *Aspergillus* species (such as those described in EP-A-0184438 and EP-A-0284603) and *Trichoderma* species; bacteria such as *Bacillus* species (such as those described in EP-A-0134048 and EP-A-0253455), *Streptomyces* species and *Pseudomonas* species; and yeasts such as *Kluyveromyces* species (such as those described in EP-A-0096430 and EP-A-0301670) and *Saccharomyces* species. By way of example, typical expression hosts may be selected from *Aspergillus niger*, *Aspergillus niger* var. *tubigenis*, *Aspergillus niger* var. *awamori*, *Aspergillus aculeatus*, *Aspergillus nidulans*, *Aspergillus oryzae*, *Trichoderma reesei*, *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Kluyveromyces lactis* and *Saccharomyces cerevisiae*.

15

The use of suitable host cells - such as yeast, fungal and plant host cells - may provide for post-translational modifications (e.g. myristylation, glycosylation, truncation, ligation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

20

ORGANISM

25 The term "organism" in relation to the present invention includes any organism that could comprise the target according to the present invention and/or products obtained therefrom. Examples of organisms may include a fungus, yeast or a plant.

The term "transgenic organism" in relation to the present invention includes any organism that comprises the target according to the present invention and/or products obtained.

30 TRANSFORMATION OF HOST CELLS/HOST ORGANISMS

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see 35 *Sambrook et al* (*Molecular Cloning: A Laboratory Manual*, 2nd edition, 1989, Cold Spring Harbor Laboratory Press) and *Ausubel et al.*, *Current Protocols in Molecular Biology* (1995), John Wiley & Sons, Inc.

If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.

5 In another embodiment the transgenic organism can be a yeast. In this regard, yeast have also been widely used as a vehicle for heterologous gene expression. The species *Saccharomyces cerevisiae* has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in *Saccharomyces cerevisiae* has been reviewed by Goodey *et al* (1987, *Yeast Biotechnology*, D R Berry *et al*, eds, pp 401-429, Allen and Unwin, London) and by King *et al* (1989, *Molecular and Cell Biology of Yeasts*, E F Walton and G T Yarrington, eds, pp 107-133, Blackie, Glasgow).

10 For several reasons *Saccharomyces cerevisiae* is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the 15 extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation 20 characteristics of *Saccharomyces cerevisiae*.

25 A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", *Yeasts*, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

Several types of yeast vectors are available, including integrative vectors, which require 30 recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.

In order to prepare the transgenic *Saccharomyces*, expression constructs are prepared by inserting the nucleotide sequence into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed. The 35 constructs contain a promoter active in yeast fused to the nucleotide sequence, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.

For the transformation of yeast several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National 5 Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, *Nature*, London, 275, 104); and Ito, H et al (1983, *J Bacteriology* 153, 163-168).

The transformed yeast cells are selected using various selective markers. Among the 10 markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, e.g. G418.

Another host organism is a plant. The basic principle in the construction of genetically 15 modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material. Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the 20 genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (*Annu Rev Plant Physiol Plant Mol Biol* [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-25 A-0449375.

Thus, the present invention also provides a method of transforming a host cell with a 25 nucleotide sequence that is to be the target or is to express the target. Host cells transformed with the nucleotide sequence may be cultured under conditions suitable for the expression of the encoded protein. The protein produced by a recombinant cell may be displayed on the surface of the cell. If desired, and as will be understood by those of skill in the art, expression vectors containing coding sequences can be designed with 30 signal sequences which direct secretion of the coding sequences through a particular prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join the coding sequence to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) *DNA Cell Biol* 12:441-53).

VARIANTS/HOMOLOGUES/DERIVATIVES

35

In addition to the specific amino acid sequences and nucleotide sequences mentioned herein, the present invention also encompasses the use of variants, homologue and

derivatives thereof. Here, the term "homology" can be equated with "identity".

In the present context, an homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below)

the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an
5 optimal alignment, taking into consideration gap penalties. A suitable computer program
for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of
Wisconsin, U.S.A.; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of
other software than can perform sequence comparisons include, but are not limited to,
the BLAST package (see Ausubel et al., 1999 *ibid* – Chapter 18), FASTA (Atschul et al.,
10 1990, *J. Mol. Biol.*, 403-410) and the GENWORKS suite of comparison tools. Both
BLAST and FASTA are available for offline and online searching (see Ausubel et al.,
1999 *ibid*, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.

A further useful reference is that found in *FEMS Microbiol Lett* 1999 May 15;174(2):247-
15 50 (and a published erratum appears in *FEMS Microbiol Lett* 1999 Aug 1;177(1):187-8).

Although the final % homology can be measured in terms of identity, the alignment
process itself is typically not based on an all-or-nothing pair comparison. Instead, a
20 scaled similarity score matrix is generally used that assigns scores to each pairwise
comparison based on chemical similarity or evolutionary distance. An example of such a
matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite
of programs. GCG Wisconsin programs generally use either the public default values or a
custom symbol comparison table if supplied (see user manual for further details). It is
preferred to use the public default values for the GCG package, or in the case of other
25 software, the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate %
homology, preferably % sequence identity. The software typically does this as part of the
sequence comparison and generates a numerical result.

30

The sequences may also have deletions, insertions or substitutions of amino acid
residues which produce a silent change and result in a functionally equivalent substance.
Deliberate amino acid substitutions may be made on the basis of similarity in polarity,
charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the
35 residues as long as the secondary binding activity of the substance is retained. For
example, negatively charged amino acids include aspartic acid and glutamic acid;
positively charged amino acids include lysine and arginine; and amino acids with

uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

5 Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
	Polar – uncharged	I L V
		C S T M
	Polar – charged	N Q
AROMATIC		D E
		K R
		H F W Y

10

EXPRESSION VECTORS

The nucleotide sequence for use as the target or for expressing the target can be incorporated into a recombinant replicable vector. The vector may be used to replicate 15 and express the nucleotide sequence in and/or from a compatible host cell. Expression may be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two or more 20 different promoters described above.

The protein produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal 25 sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

FUSION PROTEINS

30 The target amino acid sequence may be produced as a fusion protein, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-

transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and (-galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of 5 the target.

The fusion protein may comprise an antigen or an antigenic determinant fused to the substance of the present invention. In this embodiment, the fusion protein may be a non-naturally occurring fusion protein comprising a substance which may act as an adjuvant in 10 the sense of providing a generalised stimulation of the immune system. The antigen or antigenic determinant may be attached to either the amino or carboxy terminus of the substance.

In another embodiment of the invention, the amino acid sequence may be ligated to a 15 heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.

20 THERAPY

The compounds of the present invention may be used as therapeutic agents – i.e. in therapy applications.

25 The term "therapy" includes curative effects, alleviation effects, and prophylactic effects.

The therapy may be on humans or animals, preferably female animals.

PHARMACEUTICAL COMPOSITIONS

30

In one aspect, the present invention provides a pharmaceutical composition, which comprises a compound according to the present invention and optionally a pharmaceutically acceptable carrier, diluent or excipient (including combinations thereof).

35

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier, or excipient. Acceptable carriers or diluents for therapeutic

use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The 5 pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

10 Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

15 There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may 20 be designed to be delivered by both routes.

25 Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit though the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

30 Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may 35 be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be

administered in the form of tablets or lozenges which can be formulated in a conventional manner.

COMBINATION PHARMACEUTICAL

5

The compound of the present invention may be used in combination with one or more other active agents, such as one or more other pharmaceutically active agents.

By way of example, the compounds of the present invention may be used in combination

10 with other STS inhibitors and/or other inhibitors such as an aromatase inhibitor (such as for example, 4hydroxyandrostenedione (4-OHA)) and/or steroids – such as the naturally occurring 'sterneurosteroids dehydroepiandrosterone sulfate (DHEAS) and pregnenolone sulfate (PS) and/or other structurally similar organic compounds.

15 In addition, or in the alternative, the compound of the present invention may be used in combination with a biological response modifier.

The term biological response modifier ("BRM") includes cytokines, immune modulators, growth factors, haematopoiesis regulating factors, colony stimulating factors, 20 chemotactic, haemolytic and thrombolytic factors, cell surface receptors, ligands, leukocyte adhesion molecules, monoclonal antibodies, preventative and therapeutic vaccines, hormones, extracellular matrix components, fibronectin, etc. For some applications, preferably, the biological response modifier is a cytokine. Examples of cytokines include: interleukins (IL) - such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-19; Tumour Necrosis Factor (TNF) - such as TNF- α ; Interferon alpha, beta and gamma; TGF- β . For some applications, preferably the cytokine is tumour necrosis factor (TNF). For some applications, the TNF may be any type of TNF - such as TNF- α , TNF- β , including derivatives or mixtures thereof. More preferably the cytokine is TNF- α . Teachings on TNF may be found in the art - such as WO-A-98/08870 and WO-A-25

30 98/13348.

ADMINISTRATION

Typically, a physician will determine the actual dosage which will be most suitable for an 35 individual subject and it will vary with the age, weight and response of the particular

patient. The dosages below are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.

The compositions of the present invention may be administered by direct injection. The 5 composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Depending upon the need, the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

10 By way of further example, the agents of the present invention may be administered in accordance with a regimen of 1 to 4 times per day, preferably once or twice per day. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body 15 weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

Aside from the typical modes of delivery – indicated above – the term "administered" also 20 includes delivery by techniques such as lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof. The routes for such delivery mechanisms include but are not limited to mucosal, nasal, oral, parenteral, gastrointestinal, topical, or sublingual routes.

25 The term "administered" includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution; a parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route.

30 Thus, for pharmaceutical administration, the STS inhibitors of the present invention can be formulated in any suitable manner utilising conventional pharmaceutical formulating techniques and pharmaceutical carriers, adjuvants, excipients, diluents etc. and usually for parenteral administration. Approximate effective dose rates may be in the range from 1 to 1000 mg/day, such as from 10 to 900 mg/day or even from 100 to 800 mg/day depending on the individual activities of the compounds in question and for a patient of 35 average (70Kg) bodyweight. More usual dosage rates for the preferred and more active compounds will be in the range 200 to 800 mg/day, more preferably, 200 to 500 mg/day, most preferably from 200 to 250 mg/day. They may be given in single dose regimes, split

dose regimes and/or in multiple dose regimes lasting over several days. For oral administration they may be formulated in tablets, capsules, solution or suspension containing from 100 to 500 mg of compound per unit dose. Alternatively and preferably the compounds will be formulated for parenteral administration in a suitable parenterally 5 administrable carrier and providing single daily dosage rates in the range 200 to 800 mg, preferably 200 to 500, more preferably 200 to 250 mg. Such effective daily doses will, however, vary depending on inherent activity of the active ingredient and on the bodyweight of the patient, such variations being within the skill and judgement of the physician.

10

CELL CYCLING

) The compounds of the present invention may be useful in the method of treatment of a cell cycling disorder.

15

As discussed in "Molecular Cell Biology" 3rd Ed. Lodish *et al.* pages 177-181 different eukaryotic cells can grow and divide at quite different rates. Yeast cells, for example, can divide every 120 min., and the first divisions of fertilised eggs in the embryonic cells of sea urchins and insects take only 1530 min. because one large pre-existing cell is 20 subdivided. However, most growing plant and animal cells take 10-20 hours to double in number, and some duplicate at a much slower rate. Many cells in adults, such as nerve cells and striated muscle cells, do not divide at all; others, like the fibroblasts that assist in healing wounds, grow on demand but are otherwise quiescent.

25

Still, every eukaryotic cell that divides must be ready to donate equal genetic material to two daughter cells. DNA synthesis in eukaryotes does not occur throughout the cell division cycle but is restricted to a part of it before cell division.

30

The relationship between eukaryotic DNA synthesis and cell division has been thoroughly analysed in cultures of mammalian cells that were all capable of growth and division. In contrast to bacteria, it was found, eukaryotic cells spend only a part of their time in DNA synthesis, and it is completed hours before cell division (mitosis). Thus a gap of time occurs after DNA synthesis and before cell division; another gap was found to occur after division and before the next round of DNA synthesis. This analysis led to the conclusion 35 that the eukaryotic cell cycle consists of an M (mitotic) phase, a G₁ phase (the first gap), the S (DNA synthesis) phase, a G₂ phase (the second gap), and back to M. The phases between mitoses (G₁, S, and G₂) are known collectively as the interphase.

Many nondividing cells in tissues (for example, all quiescent fibroblasts) suspend the cycle after mitosis and just prior to DNA synthesis; such "resting" cells are said to have exited from the cell cycle and to be in the G_0 state.

5

It is possible to identify cells when they are in one of the three interphase stages of the cell cycle, by using a fluorescence-activated cell sorter (FACS) to measure their relative DNA content: a cell that is in G_1 (before DNA synthesis) has a defined amount x of DNA; during S (DNA replication), it has between x and $2x$; and when in G_2 (or M), it has $2x$ of

10 DNA.

The stages of mitosis and cytokinesis in an animal cell are as follows

(a) Interphase. The G_2 stage of interphase immediately precedes the beginning of 15 mitosis. Chromosomal DNA has been replicated and bound to protein during the S phase, but chromosomes are not yet seen as distinct structures. The nucleolus is the only nuclear substructure that is visible under light microscope. In a diploid cell before DNA replication there are two morphologic chromosomes of each type, and the cell is said to be $2n$. In G_2 , after DNA replication, the cell is $4n$. There are four copies of each 20 chromosomal DNA. Since the sister chromosomes have not yet separated from each other, they are called sister chromatids.

b) Early prophase. Centrioles, each with a newly formed daughter centriole, begin 25 moving toward opposite poles of the cell; the chromosomes can be seen as long threads. The nuclear membrane begins to disaggregate into small vesicles.

(c) Middle and late prophase. Chromosome condensation is completed; each visible 30 chromosome structure is composed of two chromatids held together at their centromeres. Each chromatid contains one of the two newly replicated daughter DNA molecules. The microtubular spindle begins to radiate from the regions just adjacent to the centrioles, which are moving closer to their poles. Some spindle fibres reach from pole to pole; most 35 go to chromatids and attach at kinetochores.

(d) Metaphase. The chromosomes move toward the equator of the cell, where they 35 become aligned in the equatorial plane. The sister chromatids have not yet separated.

(e) Anaphase. The two sister chromatids separate into independent chromosomes. Each contains a centromere that is linked by a spindle fibre to one pole, to which it moves. Thus one copy of each chromosome is donated to each daughter cell. Simultaneously, the cell elongates, as do the pole-to-pole spindles. Cytokinesis begins 5 as the cleavage furrow starts to form.

(f) Telophase. New membranes form around the daughter nuclei; the chromosomes uncoil and become less distinct, the nucleolus becomes visible again, and the nuclear membrane forms around each daughter nucleus. Cytokinesis is nearly complete, and the 10 spindle disappears as the microtubules and other fibres depolymerise. Throughout mitosis the "daughter" centriole at each pole grows until it is full-length. At telophase the duplication of each of the original centrioles is completed, and new daughter centrioles will be generated during the next interphase.

15 (g) Interphase. Upon the completion of cytokinesis, the cell enters the G₁ phase of the cell cycle and proceeds again around the cycle.

It will be appreciated that cell cycling is an extremely important cell process. Deviations 20 from normal cell cycling can result in a number of medical disorders. Increased and/or unrestricted cell cycling may result in cancer. Reduced cell cycling may result in degenerative conditions. Use of the compound of the present invention may provide a means to treat such disorders and conditions.

25 Thus, the compound of the present invention may be suitable for use in the treatment of cell cycling disorders such as cancers, including hormone dependent and hormone independent cancers.

30 In addition, the compound of the present invention may be suitable for the treatment of cancers such as breast cancer, ovarian cancer, endometrial cancer, sarcomas, melanomas, prostate cancer, pancreatic cancer etc. and other solid tumours.

35 For some applications, cell cycling is inhibited and/or prevented and/or arrested, preferably wherein cell cycling is prevented and/or arrested. In one aspect cell cycling may be inhibited and/or prevented and/or arrested in the G₂/M phase. In one aspect cell cycling may be irreversibly prevented and/or inhibited and/or arrested, preferably wherein cell cycling is irreversibly prevented and/or arrested.

By the term "irreversibly prevented and/or inhibited and/or arrested" it is meant after application of a compound of the present invention, on removal of the compound the effects of the compound, namely prevention and/or inhibition and/or arrest of cell cycling, are still observable. More particularly by the term "irreversibly prevented and/or inhibited and/or arrested" it is meant that when assayed in accordance with the cell cycling assay protocol presented herein, cells treated with a compound of interest show less growth after Stage 2 of the protocol I than control cells. Details on this protocol are presented below.

Thus, the present invention provides compounds which: cause inhibition of growth of oestrogen receptor positive (ER+) and ER negative (ER-) breast cancer cells *in vitro* by preventing and/or inhibiting and/or arresting cell cycling; and/or cause regression of nitroso-methyl urea (NMU)-induced mammary tumours in intact animals (i.e. not ovariectomised), and/or prevent and/or inhibit and/or arrest cell cycling in cancer cells; and/or act *in vivo* by preventing and/or inhibiting and/or arresting cell cycling and/or act as a cell cycling agonist.

CELL CYCLING ASSAY (PROTOCOL 6)

Procedure

20

Stage 1

25

MCF-7 breast cancer cells are seeded into multi-well culture plates at a density of 105 cells/well. Cells were allowed to attach and grow until about 30% confluent when they are treated as follows:

Control - no treatment

Compound of Interest (COI) 20 μ M

30

Cells are grown for 6 days in growth medium containing the COI with changes of medium/COI every 3 days. At the end of this period cell numbers were counted using a Coulter cell counter.

Stage 2

35

After treatment of cells for a 6-day period with the COI cells are re-seeded at a density of 10⁴ cells/well. No further treatments are added. Cells are allowed to continue to grow for

a further 6 days in the presence of growth medium. At the end of this period cell numbers are again counted.

CANCER

5

As indicated, the compounds of the present invention may be useful in the treatment of a cell cycling disorder. A particular cell cycling disorder is cancer.

10 Cancer remains a major cause of mortality in most Western countries. Cancer therapies developed so far have included blocking the action or synthesis of hormones to inhibit the growth of hormone-dependent tumours. However, more aggressive chemotherapy is currently employed for the treatment of hormone-independent tumours.

15 Hence, the development of a pharmaceutical for anti-cancer treatment of hormone dependent and/or hormone independent tumours, yet lacking some or all of the side-effects associated with chemotherapy, would represent a major therapeutic advance.

20 It is known that oestrogens undergo a number of hydroxylation and conjugation reactions after their synthesis. Until recently it was thought that such reactions were part of a metabolic process that ultimately rendered oestrogens water soluble and enhanced their elimination from the body. It is now evident that some hydroxy metabolites (e.g. 2-hydroxy and 16alpha-hydroxy) and conjugates (e.g. oestrone sulphate, E1S) are important in determining some of the complex actions that oestrogens have in the body.

25 Workers have investigated the formation of 2- and 16-hydroxylated oestrogens in relation to conditions that alter the risk of breast cancer. There is now evidence that factors which increase 2-hydroxylase activity are associated with a reduced cancer risk, while those increasing 16alpha-hydroxylation may enhance the risk of breast cancer. Further interest in the biological role of estrogen metabolites has been stimulated by the growing body of 30 evidence that 2-methoxyoestradiol is an endogenous metabolite with anti-mitotic properties. 2-MeOE2 is formed from 2-hydroxy estradiol (2-OHE2) by catechol estrogen methyl transferase, an enzyme that is widely distributed throughout the body.

35 Workers have shown that *in vivo* 2-MeOE2 inhibits the growth of tumours arising from the subcutaneous injection of Meth A sarcoma, B16 melanoma or MDA-MB-435 estrogen receptor negative (ER-) breast cancer cells. It also inhibits endothelial cell proliferation and migration, and *in vitro* angiogenesis. It was suggested that the ability of 2-MeOE2 to

inhibit tumour growth *in vivo* may be due to its ability to inhibit tumour-induced angiogenesis rather than direct inhibition of the proliferation of tumour cells.

The mechanism by which 2-MeOE2 exerts its potent anti-mitogenic and anti-angiogenic effects is still being elucidated. There is evidence that at high concentrations it can inhibit microtubule polymerisation and act as a weak inhibitor of colchicine binding to tubulin. Recently, however, at concentrations that block mitosis, tubulin filaments in cells were not found to be depolymerised but to have an identical morphology to that seen after taxol treatment. It is possible, therefore, that like taxol, a drug that is used for breast and ovarian breast cancer therapy, 2-MeOE2 acts by stabilising microtubule dynamics.

While the identification of 2-MeOE2 as a new therapy for cancer represents an important advance, the bioavailability of orally administered oestrogens is poor. Furthermore, they can undergo extensive metabolism during their first pass through the liver. As part of a research programme to develop a steroid sulphatase inhibitor for breast cancer therapy, oestrone-3-O-sulphamate (EMATE) was identified as a potent active site-directed inhibitor. Unexpectedly, EMATE proved to possess potent oestrogenic properties with its oral uterotrophic activity in rats being a 100-times higher than that of estradiol. Its enhanced oestrogenicity is thought to result from its absorption by red blood cells (rbc's) which protects it from inactivation during its passage through the liver and which act as a reservoir for its slow release for a prolonged period of time. A number of A-ring modified analogues were synthesised and tested, including 2-methoxyoestrone-3-O-sulphamate. While this compound was equipotent with EMATE as a steroid sulphatase inhibitor, it was devoid of oestrogenicity.

We believe that the compound of the present invention provides a means for the treatment of cancers and, especially, breast cancer.

In addition or in the alternative the compound of the present invention may be useful in blocking the growth of cancers including leukaemias and solid tumours such as breast, endometrium, prostate, ovary and pancreatic tumours.

THERAPY CONCERNING OESTROGEN

We believe that some of the compounds of the present invention may be useful in the control of oestrogen levels in the body – in particular in females. Thus, some of the compounds may be useful as providing a means of fertility control – such as an oral

contraceptive tablet, pill, solution or lozenge. Alternatively, the compound could be in the form of an implant or as a patch.

Thus, the compounds of the present invention may be useful in treating hormonal 5 conditions associated with oestrogen.

In addition or in the alternative the compound of the present invention may be useful in treating hormonal conditions in addition to those associated with oestrogen. Hence, the compound of the present invention may also be capable of affecting hormonal activity and 10 may also be capable of affecting an immune response.

NEURODEGENERATIVE DISEASES

We believe that some of the compounds of the present invention may be useful in the 15 treatment of neurodegenerative diseases, and similar conditions.

By way of example, it is believed that STS inhibitors may be useful in the enhancing the memory function of patients suffering from illnesses such as amnesia, head injuries, Alzheimer's disease, epileptic dementia, presenile dementia, post traumatic dementia, 20 senile dementia, vascular dementia and post-stroke dementia or individuals otherwise seeking memory enhancement.

TH1

25 We believe that some of the compounds of the present invention may be useful in TH1 implications.

By way of example, it is believed that the presence of STS inhibitors within the macrophage or other antigen presenting cells may lead to a decreased ability of 30 sensitised T cells to mount a TH1 (high IL-2, IFN? low IL-4) response. The normal regulatory influence of other steroids such as glucocorticoids would therefore predominate.

INFLAMMATORY CONDITIONS

35

We believe that some of the compounds of the present invention may be useful in treating inflammatory conditions - such as conditions associated with any one or more of:

autoimmunity, including for example, rheumatoid arthritis, type I and II diabetes, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, thyroiditis, vasculitis, ulcerative colitis and Crohn's disease, skin disorders e.g. psoriasis and contact dermatitis; graft versus host disease; eczema; asthma and organ rejection following transplantation.

5

By way of example, it is believed that STS inhibitors may prevent the normal physiological effect of DHEA or related steroids on immune and/or inflammatory responses.

10 The compounds of the present invention may be useful in the manufacture of a medicament for revealing an endogenous glucocorticoid-like effect.

OTHER THERAPIES

15 It is also to be understood that the compound/composition of the present invention may have other important medical implications.

For example, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-99/52890 – viz:

20 In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states,

25 graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's disease, atherosclerosis,

30 stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.

35 In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation

activity; immunosuppressant or immunostimulant activity (e.g. for treating immune deficiency, including infection with human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g.

5 treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g.

10 for treating haemophilia and stroke); antiinflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.

15 In addition, or in the alternative, the composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/09985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation; inhibit

20 the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation

25 associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other

30 glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididymo-orchitis, infertility, orchidal trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or inflammatory-

35 related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis

pigmentosa, immune and inflammatory components of degenerative fundus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against 5 ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV- 10 related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of strokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillain- 15 Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic 20 inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate 25 monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.

30 COMPOUND PREPARATION

The compounds of the present invention may be prepared by reacting an appropriate alcohol with a suitable chloride. By way of example, the sulphamate compounds of the present invention may be prepared by reacting an appropriate alcohol with a suitable 35 sulfamoyl chloride, of the formula $R_1R_2NSO_2Cl$.

Typical conditions for carrying out the reaction are as follows.

Sodium hydride and a sulfamoyl chloride are added to a stirred solution of the alcohol in anhydrous dimethyl formamide at 0°C. Subsequently, the reaction is allowed to warm to room temperature whereupon stirring is continued for a further 24 hours. The reaction 5 mixture is poured onto a cold saturated solution of sodium bicarbonate and the resulting aqueous phase is extracted with dichloromethane. The combined organic extracts are dried over anhydrous MgSO₄. Filtration followed by solvent evaporation in vacuo and co-evaporated with toluene affords a crude residue which is further purified by flash chromatography.

10

Preferably, the alcohol is derivatised, as appropriate, prior to reaction with the sulfamoyl chloride. Where necessary, functional groups in the alcohol may be protected in known manner and the protecting group or groups removed at the end of the reaction.

15

Preferably, the sulphamate compounds are prepared according to the teachings of Page *et al* (1990 *Tetrahedron* 46; 2059-2068).

The phosphonate compounds may be prepared by suitably combining the teachings of Page *et al* (1990 *Tetrahedron* 46; 2059-2068) and PCT/GB92/01586.

20

The sulphonate compounds may be prepared by suitably adapting the teachings of Page *et al* (1990 *Tetrahedron* 46; 2059-2068) and PCT/GB92/01586.

25

The thiophosphonate compounds may be prepared by suitably adapting the teachings of Page *et al* (1990 *Tetrahedron* 46; 2059-2068) and PCT/GB91/00270.

SUMMARY

In summation, the present invention provides novel compounds for use as steroid 30 sulphatase inhibitors, and pharmaceutical compositions containing them.

EXAMPLES

The present invention will now be described only by way of example with reference to the 35 accompanying drawings in which:-

Figure 1 presents general formulae;

Figure 2 presents a general reaction scheme;
Figure 3 presents a general reaction scheme;
Figure 4 presents a compound formula;
Figure 5 presents a Table of data;
5 Figure 6 presents a graph;
Figure 7 presents a compound formula;
Figure 8 presents a Table of data;
Figure 9 presents a graph;
Figure 10 presents a graph;
10 Figure 11 presents a compound formula;
Figure 12 presents a compound formula;
Figure 13 presents a graph; and
Figure 14 presents a graph.

)

15 The following compounds according to the present invention (see Figures 4, 7, 11 and 12) were prepared according to general synthetic scheme presented in Figure 2. In particular, Compounds 1,2, 3, 5, 6, 8 and 9 (see Scheme 1 in Figure 2) were prepared as described by Page *et al.* (Tetrahedron 1990; 46; 2059-2068).

20 Compounds were then tested according to the Protocols mentioned above. The results (see Figures 5, 6, 8, 9, 10, 13 and 14) showed that they were able to act as STS inhibitors.

)

25 The IC₅₀ of each of Compound 4, 7, 10 and 13 was also derived. These values are given below.

Compound	IC ₅₀	
4	2-BromoEMATE	1.65nM
7	2-IodoEMATE	6.1nM
10	2-ChloroEMATE	0.8nM
13	2-FluoroMATE	5.6nM

Oestrone acetate (1)

30 A mixture of oestrone (10 g, 36.82 mmol), acetic anhydride (17.5 ml) and pyridine (75 ml) was heated under reflux for 2 h. The cooled reaction mixture was concentrated in vacuo

and then quenched with ice-water. The precipitate that formed was filtered off, washed with water, dried, and recrystallised from aqueous ethanol (95%) to give 1 as white crystals (11.2 g, 97%); mp 115-118 °C; TLC (chloroform/acetone, 8:1); R_f 0.83; ν_{max} (KBr) 1770, 1720 (C=O) cm^{-1} ; δ_H (400 MHz, $CDCl_3$) 0.91 (3H, s, C-18- CH_3), 1.42-2.19 (11H, m), 2.29 (3H, s, CH_3CO), 2.38-2.54 (2H, m), 2.9 (2H, t, J = 4.43 Hz, C-6- CH_2), 6.81 (1H, d, $J_{C-2-H, C-4-H}$ = 2.14 Hz, C-4-H), 6.86 (1H, dd, $J_{C-4-H, C-2-H}$ = 2.44 Hz and $J_{C-1-H, C-2-H}$ = 8.54 Hz, C-2-H) and 7.28 (1H, d, $J_{C-2-H, C-1-H}$ = 8.24 Hz, C-1-H); MS m/z (FAB+) 466.2 [10, (M+H+NBA) $^+$], 313.2 [65, (M+H) $^+$], 270.2 [100, (M+H- CH_3CO) $^-$]; MS m/z (FAB-) 269.2 [100, (M- CH_3CO) $^-$]. Found C, 76.9; H, 7.83 $C_{20}H_{24}O_3$ requires C, 76.89; H, 7.74%.

2-Bromoestrone acetate (2)

To a solution of 1 (2.0 g, 6.402 mmol) in trifluoroacetic acid (TFA, 50 ml), thallic trifluoroacetate (6.958 g, 12.80 mmol) was added and the resulting mixture was stirred at 0 °C under nitrogen for 24 h. Upon removal of TFA under reduced pressure at < 40 °C, the crystalline oestrone-thallium (III) complex that obtained was washed twice with 1,2-dichloroethane. 1,4-Dioxane (30 ml) and copper bromide (8.58 g, 38.41 mmol) were then added to this washed complex and the resulting mixture was heated under reflux for 3 h. After evaporation of the solvent, water (100 ml) were then added to this washed complex. After evaporation of the solvent, water (100 ml) was added to the residue resulted and the crude product was extracted into dichloromethane (3 x 150 ml). The combined organic extracts were washed with water, dried ($MgSO_4$), filtered and evaporated. The crude product obtained was fractionated by flash chromatography (ethyl acetate/hexane, 1:4) and the pale white solid obtained (2.05 g) was further purified by recrystallization from methanol to give 2 as colourless crystals (1.79 g, 72%); mp 229-231 °C; TLC (chloroform/acetone, 8:1 and ethyl acetate/hexane, 4:1); R_f 0.89 and 0.62 respectively; ν_{max} (KBr) 1770, 1730 (C=O) cm^{-1} ; δ_H (400 MHz, $CDCl_3$) 0.91 (3H, s, C-18- CH_3), 1.25-2.3 (12H, m), 2.34 (3H, s, CH_3CO), 2.5 (1H, m), 2.86 (2H, t, J = 4.58 Hz, C-6- CH_2), 6.85 (1H, s, C-4-H) and 7.49 (1H, s, C-1-H); MS m/z (FAB+) 545.2 [90, (M+H+NBA) $^+$], 391.2 [100, (M) $^+$], 348.1 [90, (M- CH_3CO) $^+$], 330.1 (10); Acc. MS (FAB+) 391.08559 $C_{20}H_{24}BrO_3$ requires 391.09088. Found C, 61.2; H, 5.89; $C_{20}H_{23}BrO_3$ requires C, 61.39; H, 5.92%.

2-Bromoestrone (3)

A mixture of 3 (1.5 g, 3.832 mmol), potassium carbonate (2.65 g, 19.17 mmol) in methanol (70 ml) was heated under reflux for 3 h. Upon evaporation of the solvent, water (50 ml) was added to the residue obtained and the crude product was extracted with dichloromethane (3 x 100 ml). The combined organic extracts were washed with water, dried (MgSO_4), filtered and evaporated to give a yellow solid (1.3 g) which was purified by recrystallization from ethyl acetate/petroleum ether (60-80 °C) (3:2) to give 3 as pale yellow crystals (1.23 g, 93%) mp 190-193 °C; TLC (chloroform/acetone, 8:1 and 4:1): R_f 0.51 and 0.64 respectively; ν_{max} (KBr) 1710 (C=O) cm^{-1} ; δ_{H} (400 MHz, CDCl_3) 0.87 (3H, s, CH_3), 1.4-2.52 (13H, m), 2.84 (2H, m, C-6- CH_2), 5.32 (1H, br s, exchanged with D_2O , OH), 6.73 (1H, s, C-4-H) and 7.52 (1H, s, C-1-H); δ_{C} (400 MHz, CDCl_3) 13.81 (q, C-18), 21.56 (t), 25.89 (t), 26.26 (t), 29.9 (t), 31.54 (t), 31.91 (t), 38.04 (d), 43.6 (d), 47.93 (s, C13), 50.38 (d), 114.94 (d, C-4), 135.04 (d, C-1), 128.84 (s), 130.92 (s), 139.02 (s), 152.7 (s, C-3) and 220 (s, C-17-C=O); MS m/z (FAB+) 502.1 [20, ($\text{M}+\text{NBA}$) $^+$], 349.1 [100, (M) $^+$], 271.0 (20); MS m/z (FAB-) 502.2 [40, ($\text{M}+\text{NBA}$) $^-$], 348.1 [100, ($\text{M}-\text{H}$) $^-$]; Acc. MS (FAB+) 348.07532 $\text{C}_{18}\text{H}_{21}\text{BrO}_2$ requires 348.07249. Found C, 60.72; H, 5.94. $\text{C}_{18}\text{H}_{21}\text{BrO}_2$ requires C, 61.9; H, 6.06%.

2-Bromoestrone 3-O-sulphamate (4)

Upon sulphonylation, 3 (500 mg, 1.431 mmol) gave a crude product (620 mg) which was fractionated by flash chromatography (chloroform/acetone, 8:1). The beige residue obtained (510 mg) was further purified by recrystallization from acetone/hexane (1:2) to give 3 as beige crystals (405 mg, 66%) mp > 155 °C (dec.); TLC (chloroform/acetone, 8:1 and 4:1): R_f 0.43 and 0.61 respectively; ν_{max} (KBr) 3500, 3300 (NH₂), 1730 (C=O), 1390 (SO_2N) cm^{-1} ; δ_{H} (400 MHz, acetone-d₆) 0.92 (3H, s, CH_3), 1.41-2.49 (13H, m), 2.86 (2H, m, C-6- H_2), 7.27 (1H, s, C-4-H), 7.32 (2H, br s, exchanged with D_2O , OSO_2NH_2) and 7.55 (1H, s, C-1-H); MS m/z (FAB+) 428.1 [100, (M) $^+$], 349.2 [40, ($\text{M}+\text{H}-\text{SO}_2\text{NH}_2$) $^+$]; MS m/z (FAB-) 580.2 [$\text{M}-\text{H}+\text{NBA}$], 428.1 [100, (M) $^-$], 349.1 [30, ($\text{M}+\text{H}-\text{SO}_2\text{NH}_2$) $^-$]; Acc. MS (FAB+) 428.04299 $\text{C}_{18}\text{H}_{23}\text{BrNO}_4\text{S}$ requires 428.05311. Found, C, 49.1; H, 5.18; N, 3.60; $\text{C}_{18}\text{H}_{22}\text{BrNO}_4\text{S}$ requires C, 50.47; H, 5.18; N, 3.27%.

2-Iodoestrone acetate (5)

This was prepared from 1 (5.0 g, 16.01 mmol) in the same manner as the preparation of 2 except that copper iodide (18.29 g, 96.03 mmol) was used. The crude product obtained was purified by flash chromatography with ethyl acetate/hexane (1:4), and the yellow solid 5 obtained (6.25 g) was further purified by recrystallization from methanol to give 5 as pale yellow crystals (5.89 g, 84%); mp 170-172°C (crystals turned brown at > 145°C); TLC (chloroform/acetone, 8:1 and ethyl acetate, 4:1): R_f 0.8 and 0.67 respectively; ν_{max} (KBr) 1770, 1730 (C=O), δ_{H} (400 MHz, CDCl₃) 0.92 (3H, s, C-18-CH₃), 1.4-2.31 (12H, m), 2.34 (3H, s, CH₃CO), 2.5 (1H, m), 2.87 (2H, t, *J* = 4.27 Hz, C-6-CH₂), 6.82 (1H, s, C-10-H) and 7.69 (1H, s, C-1-H); MS *m/z* (FAB+) 592.1 [20, (M+H+NBA)⁺], 439.1 [80, (M+H)⁺], 396.1 [100, (M+H-CH₃CO)⁺], 270.2 (40); Acc. MS (FAB+) 439.07667 C₂₀H₂₄IO₃ requires 439.07702. Found C, 54.2; H, 5.3 C₂₀H₂₃IO₃ requires C, 54.81; H, 5.29%.

15 2-Iodoestrone (6)

This was prepared from 5 (4.0 g, 9.126 mmol) in the same manner as the preparation of its bromo analogue 3. The yellow crude product obtained was recrystallized from methanol to give 6 as pale yellow crystals (3.29 g, 91%); mp 207-209 °C (crystals turned brown at > 169 °C); TLC (chloroform/acetone, 8:1): R_f 0.75; ν_{max} (KBr) 3400 (OH), 1730 (C=O) cm⁻¹; δ_{H} (270 MHz, CDCl₃) 0.91 (3H, s, C-18-CH₃), 1.4-2.56 (13H, m), 2.83 (2H, m, C-6-CH₂), 5.24 (1H, s, exchanged with D₂O, C-3-OH), 6.74 (1H, s, C-4-H) and 7.52 (1H, s, C-1-H); δ_{C} (400 MHz, CDCl₃) 13.82 (q, C-18), 21.57 (t), 25.89 (t), 26.26 (t), 29.98 (t), 31.57 (t), 31.81 (t), 39.0 (d), 43.9 (d), 48.3 (s, C13), 50.38 (d), 116.54 (d, C-4), 138.14 (d, C-1), 129.64 (s), 131.92 (s), 138.02 (s), 153.6 (s, C-3) and 220 (s, C-17, C=O); MS *m/z* (FAB+) 25 550.1 [20, (M+H+NBA)⁺], 396.1 [100, (M)⁺], 271.2 (40); MS *m/z* (FAB-) 549.2 [20, (M+NBA)⁻], 395.1 [100, (M-H)⁻]; Acc. MS (FAB+) 397.0651 C₁₈H₂₂IO₂ requires 397.06646. Found C, 53.7; H, 5.34 C₁₈H₂₁IO₂ requires C, 54.56; H, 5.34%.

2-Iodoestrone 3-O-sulphamate (7)

30 Upon sulphonylation, 6 (500 mg, 1.262 mmol) gave a crude product which was fractionated by flash chromatography (chloroform/acetone, 8:1). The beige residue that obtained (450 mg) was further purified by recrystallization from acetone/hexane (1:2) to give 7 as beige crystals (342 mg, 57%); mp > 145 °C (dec.); TLC (chloroform/acetone, 8:1

and 4:1): R_f s 0.61 and 0.73 respectively; ν_{max} (KBr) 3500, 3200 (NH₂), 1720 (C=O), 1390 (SO₂) cm^{-1} ; δ_H (400 MHz, acetone-d₆) 0.92 (3H, s, CH₃), 1.4-2.53 (13H, m), 2.83 (2H, m, C-6-H₂), 7.25 (1H, s, C-4-H), 7.32 (2H, br s, exchanged with D₂O, OSO₂NH₂) and 7.76 (1H, s, C-1-H); MS m/z (FAB+) 629.1 [40, (M+H+NBA)⁺], 476.1 [100, (M+H)⁺], 5 396.1 [40, (M+H-SO₂NH₂)⁺]; MS m/z (FAB-) 628.1 [35, (M+NBA)⁻], 474.1 [100, (M-H)⁻], 395.1 [20, (M-SO₂NH₂)⁻]; Acc. MS (FAB+) 476.03874 C₁₈H₂₃INO₄S requires 476.03926. Found, C, 45.8; H, 4.74; N, 2.85; C₁₈H₂₂INO₄S requires C, 45.48; H, 4.66; N, 2.95%.

10 The title compound – which is pictorially presented in Figure 7 - is sometimes referred to as "2-IodoEMATE". Results for this compound are presented in Figures 8 and 9. }

2-Chloroestrone acetate (8)

This was prepared from 1 (500 mg, 1.603 mmol) in the same manner as the preparation of 15 2 except that copper chloride (475 mg, 4.798 mmol) was used. The crude product obtained was purified by flash chromatography with ethyl acetate/hexane (1:4), and the pale yellow solid obtained (526 mg) was further purified by recrystallization from methanol to give 8 as white crystals (436 mg, 78%); mp 195-197°C; TLC (chloroform/acetone, 8:1 and ethyl acetate, 4:1): R_f s 0.78 and 0.67 respectively; ν_{max} 20 (KBr) 1770, 1730 (C=O), δ_H (400 MHz, CDCl₃) 0.90 (3H, s, C-18-CH₃), 1.38-2.29 (12H, m), 2.33 (3H, s, CH₃CO), 2.5 (1H, m), 2.87 (2H, m, C-6-CH₂), 6.85 (1H, s, C-4-H) and 7.34 (1H, s, C-1-H).

2-Chlorooestrone (9)

25 This was prepared from 8 (400 mg, 1.15 mmol) in the same manner as the preparation of its bromo analogue 3. The pale yellow crude product obtained was recrystallized from methanol to give 9 as white crystals (320 mg, 90%); mp 221-223 °C; TLC (chloroform/acetone, 8:1): R_f 0.70; ν_{max} (KBr) 3400 (OH), 1730 (C=O) cm^{-1} ; δ_H (270 MHz, CDCl₃) 0.91 (3H, s, C-18-CH₃), 1.4-2.54 (13H, m), 2.84 (2H, m, C-6-CH₂), 5.27 30 (1H, s, exchanged with D₂O, C-3-OH), 6.71 (1H, s, C-4-H) and 7.31 (1H, s, C-1-H).

2-Chloroestrone 3-O-sulphamate (10)


Upon sulphonylation, 6 (200 mg, 655 μ mol) gave a crude product which was fractionated by flash chromatography (chloroform/acetone, 8:1). The beige residue that obtained (190 mg) was further purified by recrystallization from acetone/hexane (1:2) to give 10 as white crystals (170 mg, 68%); mp > 163 °C (dec.); TLC (chloroform/acetone, 8:1 and 4:1): R_f s 0.63 and 0.74 respectively; ν_{max} (KBr) 3500, 3200 (NH₂), 1720 (C=O), 1390 (SO₂) cm^{-1} ; δ_H (400 MHz, CDCl₃/DMSO-d₆; 10:1) 0.93 (3H, s, CH₃), 1.4-2.51 (13H, m), 2.86 (2H, m, C-6-H₂), 7.01 (2H, br s, exchanged with D₂O, OSO₂NH₂), 7.25 (1H, s, C-4-H) and 7.35 (1H, s, C-1-H).

10

2-Fluoroestrone acetate (11)

Oestrone (1.50 g, 5.5 mmol) and *N*-fluoropyridinium triflate (2.74 g, 11.0 mmol) in 1,1,2-trichloroethane (24 ml) were refluxed under nitrogen for 24 hours. Solvent was removed under reduced pressure, and the residue poured into water and extracted with dichloromethane (3 x 100 ml), dried (MgSO₄), filtered and evaporated to give a crude brown oil which was dissolved in pyridine (10.5 ml) and treated with acetic anhydride (2.62 ml) under reflux for two hours. The solvent was evaporated and the residue poured into ice-water. The solution was extracted with dichloromethane (3 x 100 ml) dried (MgSO₄), filtered and evaporated to give a crude solid. Purification by flash-column chromatography using petroleum ether (b.p. 60-80 °C): ethyl acetate (9:1 to 7:3) as eluent afforded 0.85 g of a crude mixture after evaporation. Recrystallization from petroleum ether (b.p. 60-80 °C): absolute ethanol (2:8) gave as first crop the 2-fluoroestrone acetate 11 predominantly (purity 75-80 % estimated by ¹H NMR) (215 mg, 12 % yield) as colourless crystals.

25



Ref. See P. C. Bulman Page, F. Hussain, J.L. Maggs, P. Morgan and B. Kevin Park, *Tetrahedron*, **46**, 2059-2068, 1990.

C₂₀H₂₃FO₃

MW 330.39


Mp °C 83-88 (litt. 88-90)

¹H NMR 270 MHz (CDCl₃): 0.91 (s, 3H, C-18-CH₃), 1.38-1.75 (m, 6H), 1.90-2.45 (m, 6H), 2.32 (s, 3H, CH₃) 2.46-2.57 (m, 1H), 2.80-2.95 (m, 2H, C-6-H), 6.83 (d, 1H, *J* = 8.3 Hz, C-4-H), 7.07 (d, 1H, *J* = 13.2 Hz, C-1-H).

M/S *m/z* (+ve FAB, rel. int.): 331.1 (59, M⁺+1), 288.1 (100), 270.1 (22).HRMS (+ve FAB) *m/z* calcd for C₂₀H₂₃FO₃ (M⁺+1) 331.170948, found 331.170464.**2-Fluoroestrone (12)**

2-Fluoroestrone acetate 11 (185 mg, 0.56 mmol) was dissolved in methanol (5 ml) and deacetylated by heating with K₂CO₃ (387 mg, 5 equiv.) under reflux for 3 hours. After evaporation of the solvent, water (25 ml) was added and the product extracted by dichloromethane (3 x 20 ml). The extract was dried over MgSO₄, evaporated under reduced pressure. Recrystallisation from petroleum ether (b.p. 60-80 °C): absolute ethanol (2:8) gave 2-fluoroestrone (121 mg, purity estimated by ¹H NMR 75%) as colourless crystal (m.p. 220-227 °C). Further purification by HPLC preparative, solvent MeOH:H₂O = 60:40, flow 20 ml/min, Column Waters Radialpak C18 100 x 25 mm, detection 254 & 270 nm gave, after evaporation of the solvents, 2-fluoroestrone 12 as a white solid (72 mg, 45 % yield).

20

Ref. See P.C. Bulman Page *et al.*, *Tetrahedron*, 46, 2059-2068, 1990.C₁₈H₂₁FO₂

MW 288.36

Mp °C 220-223 [Litt. 220-222 (petroleum ether-absolute ethanol)]

¹H NMR 400 MHz (CDCl₃): 0.78 (s, 3H, C-18-CH₃), 1.37-1.79 (m, 6H), 1.91-2.40 (m, 6H), 2.46-2.56 (m, 1H), 2.80-2.90 (m, 2H, C-6-H), 5.02 (d, 1H exch. D₂O, *J* = 3.9 Hz, -OH), 6.72 (d, 1H, *J* = 9.4 Hz, C-4-H), 6.98 (d, 1H, *J* = 12.5 Hz, C-1-H).

¹⁹F NMR 376 MHz (CDCl₃): -144.50 (t, 1F, *J* = 9.2 Hz).

HPLC Waters: eluent MeOH:H₂O = 60:40, flow 2 ml/min, Column Waters Radialpak C18 8 x 100 mm, detection 270 nm, 2-fluoroestrone RT = 11.69 min 96.85%, impurity RT = 9.69 min, 3.15%.


M/S *m/z* (+ve FAB, rel. int.): 289.0 [100, (M⁺+1)], 149.0 (33), 120.0 (35).

5 M/S *m/z* (-ve FAB, rel. int.): 287.1.0 [100, (M⁻-1)], 200.0 (25), 140.0 (25), 123.0 (43).

HRMS (+ve FAB) *m/z* calcd for C₁₈H₂₁FO₂, M⁺ 288.152558, found 288.151993.

2-Fluoroestrone-3-*O*-sulphamate (13)

To a stirred solution of 2-fluoroestrone 12 (65 mg, 0.23 mmol) in anhydrous DMF (7 ml) 10 under an atmosphere of nitrogen was added at room temperature DMBP (139 mg, 0.68 mmol) then a solution of sulphonyl chloride 0.68 M in toluene (1.61 ml, 1.13 mmol) *via* syringe. The reaction mixture was stirred at room temperature for 18 hours. Water (50 ml) and ethyl acetate (60 ml) were added and upon separation, the organic layer was washed with brine (3 x 50 ml). The organic layer was dried over magnesium sulfate, filtered and 15 evaporated under reduced pressure. The obtained crude product was purified by flash chromatography (column Ø = 2.5 cm, h = 20 cm) using as eluent chloroform: acetone = 8:1 to afford 2-fluoroestrone-3-*O*-sulphamate 13 as a white solid, (47 mg, 57 % yield).



20 C₁₈H₂₂NO₄FS
MW 367.44
Mp 189-193°C

25 ¹H NMR 400 MHz (CDCl₃): 0.91 (s, 3H, C-18-CH₃), 1.36-1.70 (m, 6H), 1.92-2.36 (m, 6H), 2.46-2.57 (m, 1H), 2.80-2.95 (m, 2H, C-6-H), 5.03 (s broad, 2H exch. D₂O, -NH₂), 7.11 (d, 1H, J = 9.7 Hz, C-4-H), 7.13 (d, 1H, J = 15.5 Hz, C-1-H).

19F NMR 376 MHz (CDCl₃): -113.24 (dd, 1F, J = 15.5 Hz and J = 9.7 Hz)

M/S *m/z* (+ve FAB, rel. int.): 367.0 (100, M⁺), 350.0 (30), 288.1 (49), 258.0 (32), 243.1 (38), 178 (34), 133.0 (30), 97.0 (35).

M/S *m/z* (-ve FAB, rel. int.): 366.0 [100, (M-H)⁻], 77.9 (21).

HRMS (+ve FAB) m/z calcd for $C_{18}H_{22}NO_4S M^+$ 367.125358, found 367.126663

Rf 0.32 (CHCl₃:acetone = 8:1), SM Rf 0.58

Inhibition of Oestrone Sulphatase Activity by Halo-EMATEs in placental microsomes

5

A sulphatase - positive human placenta was used as a source of placental microsomes. Tissue was homogenised and nuclei and cell debris removed by centrifugation at 2000 x g for 30 min. Placental microsomes were obtained by centrifugation of the resulting supernatant at 100,000 x g for 1h.

10

For inhibition studies placental microsomes (125 μ g/ml) were incubated in the absence or presence of inhibitors (1pm - 1.0 μ M) with 3 H estrone sulphate (E1S, 2×10^5 dpm adjusted to 20 μ M with unlabelled E1S for 60 mins. [4- 14 C E1] (7×10^3 dpm) was added to correct for procedural losses and free and sulphated steroids separated by solvent partition using toluene. A portion of the solvent was removed and the 3 H and 14 C content determined by liquid scintillation spectrometry.

The data obtained are represented in Figure 13.

20 Further data are given in the table below.

Compound	Plate Assay in MCF -7 cells % Inhibition at 10 μ M
2-Cl-Emate	35
2-Br-Emate	33
2-I-Emate	25

Effect of Halo-EMATES on T47D Cell Growth (Plate Assay)

25 T47D receptor positive breast cancer cells were seeded into a 96 well cell culture plate and allowed to grow until approximately 70% confluent. Cells were treated with either vehicle (controls, tetrahydrofuran in medium) or halo-EMATEs (1 or 10 μ M) and cultured for a further 24h. At the end of this period effects of the drugs on cell numbers were determined using a microtitre plate assay (Cell Titre 96 cell proliferation assay, Promega).
30 In this assay the conversion of substrate by untreated cells at the end of the culture period

was set at 100%.

The data obtained are represented in Figure 14.

5 Further data are given in the table below.

Compound	Cell assay of T47D cells		
	% Inhibition at 1 μ M	% Inhibition at 10 μ M	Morphology
2-F-Emate	<1	30	+
2-Cl-Emate	1	7.5	+
2-Br-Emate	-	-	+
2-I-Emate	-	-	+

10 + has effect on cell morphology

All publications and patents mentioned in the above specification are herein incorporated by reference.

15 Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying 20 out the invention which are obvious to those skilled in chemistry, biology or related fields are intended to be within the scope of the following claims.

CLAIMS

1. A compound of the formula (Ia) as presented in Figure 1; wherein:
 - 5 X is a ring having at least 4 atoms in the ring;
 - K is a hydrocarbyl group;
 - Rh1 is an optional halo group;
 - Rh2 is an optional halo group;
 - 10 at least one of Rh1 and Rh2 is present;
 - Rs is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group;
 - and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity.
- 15 2. A compound according to claim 1 wherein X in combination with Y mimics a steroidal structure.
3. A compound according to claim 1 or claim 2 wherein K is a cyclic group.
- 20 4. A compound according to any one of the preceding claims wherein X is a six-membered ring.
5. A compound according to any one of the preceding claims wherein X in combination with Y is a steroidal ring structure.
- 25 6. A compound according to any one of the preceding claims wherein Rs is a sulphamate group.
7. A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in any one of the preceding claims; (b) determining whether one or more of said candidate compounds is/are capable of modulating STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of modulating STS activity.
- 35 8. A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in any one of the preceding claims; (b) determining whether one or more of said candidate compounds is/are capable of

inhibiting STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting STS activity.

9. A compound identified by the method according to claim 7 or claim 8.

5

10. A compound according to any one of the preceding claims for use in medicine.

11. A pharmaceutical composition comprising the compound according to any one of the preceding claims optionally admixed with a pharmaceutically acceptable carrier,

10 diluent, excipient or adjuvant.

12. Use of a compound according to any one of the preceding claims in the manufacture of a medicament for use in the therapy of a condition or disease associated with STS.

15

13. Use of a compound according to any one of the preceding claims in the manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels.

1 / 10




FIG 1a





FIG 1b

2 / 10



Scheme 1: Synthesis of 2-Bromo and 2-Iodoestrone-3-O-sulphamates.

FIG.2

SUBSTITUTE SHEET (RULE 26)

3 / 10




FIG.3

Scheme 2 : Synthesis of 2-FluoroEMATE

4 / 10




FIG.4

Mean % Inhibition	SD % Inhibition	Treatments
99.6	0.1	2SBH29F1 (2-BromoEMATE) 10µM
98.8	0.1	2SBH29F1 (2-BromoEMATE) 1µM
94.5	0.2	2SBH29F1 (2-BromoEMATE) 0.1µM
85.1	0.1	2SBH29F1 (2-BromoEMATE) 10nM
72.1	0.2	2SBH29F1 (2-BromoEMATE) 1nM
46.1	0.3	2SBH29F1 (2-BromoEMATE) 0.1nM
32.2	0.5	2SBH29F1 (2-BromoEMATE) 10pM
19.7	1.2	2SBH29F1 (2-BromoEMATE) 1pM
6.1	1.2	2SBH29F1 (2-BromoEMATE) 0.1pM
-6.7	0.7	2SBH29F1 (2-BromoEMATE) 10fM
98.8	0.1	EMATE 10µM
95.1	0.1	EMATE 1µM
74.4	1.1	EMATE 0.1µM
24.3	3.5	EMATE 10nM
-0.9	1.2	EMATE 1nM

FIG.5

5 / 10




FIG.6




FIG.7

SUBSTITUTE SHEET (RULE 26)

6 / 10

Inhibition of placental steroid sulphatase activity		
Mean % Inhibition	SD % Inhibition	Concentration of 2-Iodo Emate
98.8	0.1	10µM 2SBH30F1
97.3	0.1	1µM 2SBH30F1
89.8	0.6	0.1µM 2SBH30F1
72.9	0	10nM 2SBH30F1
51.1	1.7	1nM 2SBH30F1
30.1	0.6	0.1nM 2SBH30F1
13.1	0.5	10pM 2SBH30F1

FIG.8




FIG.9

SUBSTITUTE SHEET (RULE 26)

7 / 10




FIG.10

8 / 10




FIG.11




FIG.12

9 / 10





FIG.13

10 / 10

**FIG.14**

INTERNATIONAL SEARCH REPORT

Intern:	Application No
PCT/GB 00/04689	

A. CLASSIFICATION OF SUBJECT MATTER			
IPC 7	C07J41/00	A61K31/565	A61P5/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07J A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

CHEM ABS Data, BIOSIS, WPI Data, EPO-Internal, PAJ
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 24802 A (POTTER BARRY VICTOR LLOYD ; REED MICHAEL JOHN (GB); IMPERIAL COLLEG) 11 June 1998 (1998-06-11) page 3, line 4-10 page 10, paragraph 2 page 21 -page 22; table 1 ---	1-13
Y	page 3, line 4-10 page 10, paragraph 2 page 21 -page 22; table 1 ---	1-13
X	WO 93 05064 A (IMPERIAL COLLEGE) 18 March 1993 (1993-03-18) page 2, line 21-27 page 5, line 13-20; examples 1-8 ---	1-13
X	WO 93 05063 A (IMPERIAL COLLEGE) 18 March 1993 (1993-03-18) page 3, line 23-27 page 6, line 9-16; examples 1-8 ---	1-13
		-/-

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
--	--

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search	Date of mailing of the International search report
---	--

28 March 2001	12/04/2001
---------------	------------

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer
---	--------------------

Authorized officer

Wachtorn, P

INTERNATIONAL SEARCH REPORT

Interr	Application No
PCT/GB 00/04689	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 27936 A (POTTER BARRY VICTOR LLOYD ;REED MICHAEL JOHN (GB); UNIV BATH (GB);) 10 June 1999 (1999-06-10) page 3, paragraph 3 page 10, line 16-21; examples 1-3 ---	1-13
Y	PUROHIT A ET AL: "THE DEVELOPMENT OF A-RING MODIFIED ANALOGUES OF OESTRONE-3-O-SULPHAMATE AS POTENT STEROID SULPHATASE INHIBITORS WITH REDUCED OESTROGENICITY" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, GB, ELSEVIER SCIENCE LTD., OXFORD, vol. 64, no. 5, 1998, pages 269-275, XP000852539 ISSN: 0960-0760 page 271, column 2; table 1 ---	1-13
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996 WOO L W LAWRENCE ET AL: "Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism." Database accession no. PREV199699047240 XP002164108 abstract & JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 57, no. 1-2, 1996, pages 79-88, ISSN: 0960-0760 ---	1-13
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994 PUROHIT A ET AL: "Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: Potential therapeutic agents in breast cancer." Database accession no. PREV199497287252 XP002164109 abstract & JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 48, no. 5-6, 1994, pages 523-527, ISSN: 0960-0760 --- -/-	1-13

INTERNATIONAL SEARCH REPORT

Item	Application No
PCT/GB 00/04689	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE BIOSIS 'Online!' BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993 HOWART NICOLA M ET AL: "Phosphonates and thiophosphonates as sulfate surrogates: Synthesis of estrone 3-methylthiophosphonate, a potent inhibitor of estrone sulfatase." Database accession no. PREV199395110824 XP002164110 abstract & BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 2, 1993, pages 313-318, ISSN: 0960-894X</p> <p>---</p>	1-13
Y	<p>TOWNSLEY J D: "FURTHER STUDIES ON THE REGULATION OF HUMAN PLACENTAL STEROID 3-SULFATASE ACTIVITY" ENDOCRINOLOGY, US, BALTIMORE, MD, vol. 93, no. 1, 1 July 1973 (1973-07-01), pages 172-181, XP002068155 ISSN: 0013-7227 page 176; table 4</p> <p>---</p>	1-13
A	<p>US 4 496 555 A (BROOKS SAMUEL C ET AL) 29 January 1985 (1985-01-29) column 6, line 45-48; examples 2,3</p> <p>---</p>	1-13
A	<p>HORWITZ, JEROME P. ET AL: "In vitro inhibition of estrogen sulfoconjugation by some 2- and 4-substituted estra-1,3,5(10)-trien-17.beta.-ols" J. MED. CHEM. (1986), 29(5), 692-8 , XP002164107 page 692, column 2; table I</p> <p>---</p>	1-13

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-13 (all in part)

Present claims 1-6,9 relate to an extremely large number of possible compounds. In fact, the claims embrace so many possible structures that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely the 2-halogenated estrone derivatives of the examples.

Present claims 1-6,9 seek to limit the structurally defined part of the compounds claimed therein by reference to a desirable characteristic or property, namely that the compounds falling within the structural formula defined there must also be inhibitors of the enzyme Steroid Sulphatase in order to be covered by these claims.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the 2-halogenated estrone derivatives of the examples.

In this regard it must also be noted, that the skilled person is presented with a set of compound claims which give a structural definition of exceptionally great breadth by virtue of the extremely broad definition of the variable structural features used therein. The claim then attempts to limit the scope of these compound claims by introducing the limiting feature that the compounds embraced by this structural formula, must also be inhibitors of the above mentioned enzyme. This implies very strongly that not all structural possibilities falling within the structural definition are capable of inhibiting the above mentioned enzyme. Since the inhibition of this enzyme is indeed the problem to be solved (see page 3, lines 9-10 of the description), the applicant has defined the compounds of claims 1-6 in the form of a desideratum, since the structural definition given in claims 1-6,9 is effectively meaningless by virtue of its excessive breadth, the only meaningful technical feature of these claims is the above mentioned functional feature. Given that this function (the inhibition of the steroid sulphatase enzyme) is also the problem to be solved, the applicant has effectively defined his (alleged) invention in the claims

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

in terms of it being a solution to this problem - this is a desideratum, which renders these claims insufficiently disclosed according to Article 5 PCT, since the skilled person is given no pointer in these claims as to which of the compounds falling within the broad structural definition are actually able to solve this problem. Effectively, in order for a skilled person to arrive at compounds solving this problem from the combination of the desideratum and the broad structural formula, they would have to exercise an inventive step according to Article 33(3) PCT, which means that the invention as defined in claims 1-6 is insufficiently disclosed within the meaning of Article 5 PCT.

The only meaningful disclosure which could be ascertained from the disclosure of the present application which is clear and supported (Article 6 PCT) and sufficiently disclosed to a degree which permits a meaningful search, is that relating to the 2-halogenated estrone derivatives of the examples.

The scope of the search on the pharmaceutical compositions, diagnostic methods and first and second medicinal indications of claims 7,8,10-13 has been limited to pharmaceutical compositions, diagnostic methods and first and second medicinal indications involving the 2-halogen substituted estrone compounds of the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No
PCT/GB 00/04689

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9824802	A 11-06-1998	AU 5402398 A EP 0942919 A		29-06-1998 22-09-1999
WO 9305064	A 18-03-1993	AT 194843 T AU 717116 B AU 1007799 A AU 668882 B AU 2490592 A AU 689043 B AU 5837396 A AU 7195298 A BR 9206434 A CA 2114630 A CZ 9400440 A DE 69231280 D DE 69231280 T EP 0641355 A EP 0928609 A EP 0921130 A EP 0982032 A ES 2148178 T FI 940903 A FI 20002259 A FI 20002260 A FI 20002261 A HU 66097 A JP 2000038341 A JP 7501515 T JP 2000355542 A JP 2000355598 A LV 12618 A NO 940635 A NO 995075 A NO 995076 A NO 2595 A SK 24694 A US 6011024 A US 6159960 A US 5616574 A US 5830886 A		15-08-2000 16-03-2000 04-03-1999 23-05-1996 05-04-1993 19-03-1998 05-09-1996 13-08-1998 27-09-1994 18-03-1993 18-01-1995 24-08-2000 30-11-2000 08-03-1995 14-07-1999 09-06-1999 01-03-2000 16-10-2000 20-04-1994 13-10-2000 13-10-2000 13-10-2000 28-09-1994 08-02-2000 16-02-1995 26-12-2000 26-12-2000 20-02-2001 29-04-1994 29-04-1994 29-04-1994 29-04-1994 09-11-1994 04-01-2000 12-12-2000 01-04-1997 03-11-1998
WO 9305063	A 18-03-1993	AT 191221 T AU 2494992 A DE 69230857 D DE 69230857 T EP 0602123 A JP 7501514 T US 6017904 A US 5604215 A US 5861390 A		15-04-2000 05-04-1993 04-05-2000 02-11-2000 22-06-1994 16-02-1995 25-01-2000 18-02-1997 19-01-1999
WO 9927936	A 10-06-1999	GB 2331987 A AU 1345899 A EP 1051178 A		09-06-1999 16-06-1999 15-11-2000
US 4496555	A 29-01-1985	NONE		

Form PCT/ISA/210 (patent family annex) (July 1992)

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)